Group One Trading, L.P. I Mab Transaction History

Group One Trading, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$4.01 - $12.34 $94,571 - $291,026	-23,584 Reduced 92.28%	1,974 $8,000
Q2 2022 Aug 11, 2022	BUY	$8.27 - $18.43 $211,364 - $471,033	25,558 New	25,558 $289,000
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $8,920 - $13,171	-156 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$47.86 - $83.95 $7,466 - $13,096	156 New	156 $13,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.